Ascendis Pharma grants 29K employee warrants

Ascendis Pharma granted 29,380 employee warrants at a $270.09 exercise price, with additional capacity remaining for future warrant grants.

Rhea-AI Filing Summary

Ascendis Pharma A/S (ASND) reports that its board granted an aggregate of 29,380 warrants to certain employees on September 8, 2026 under Appendix 1a to its Articles of Association. Each warrant entitles the holder to subscribe for one ordinary share at an exercise price of $270.09 per share, equal to the closing market price on the grant date.

Twenty‑five percent of the warrants vest on the one‑year anniversary of grant, with the remaining 75% vesting in equal monthly installments over the following 36 months, subject to continued service, with potential earlier vesting upon certain exit events. After this grant, warrants to subscribe for an additional 1,495,063 shares remain available for future grants under the Articles of Association.

Filing Explained

The report adds registration context but records only conditional warrant rights, so potential dilution is not a completed share issuance.

As a Form 6-K, this is an interim report from a foreign private issuer: the company reports a warrant grant dated September 8, 2026 and incorporates that disclosure into existing S-8 and F-3 registration statements.

The disclosed state is a grant of rights, not an issuance of ordinary shares: each right can lead to one share only after the stated vesting conditions and exercise. That distinction leaves a conditional dilution path for existing holders if the rights vest and are exercised, while the remaining 1,495,063-share reserve is capacity for future grants rather than a committed issuance.

Incorporation by reference places the report into those registration statements from the filing date, but does not change the grant's disclosed lifecycle state. The next state change is vesting and later exercise; the filing does not report either a completed exercise or an issuance.

Key Figures

Warrants granted: 29,380 warrants Exercise price: $270.09 per share Additional warrants available: 1,495,063 warrants +2 more

5 metrics

Warrants granted 29,380 warrants Employee warrants granted on September 8, 2026

Exercise price $270.09 per share Exercise price for each new warrant, equal to closing share price on grant date

Additional warrants available 1,495,063 warrants Warrants remaining for future grant after this issuance

Initial vesting portion 25% Vests on the one‑year anniversary of grant

Remainder vesting schedule 75% over 36 months Vests at 1/36th per month starting one year after grant

Key Terms

Form 6-K, warrants, ordinary share, Articles of Association

4 terms

Form 6-K regulatory

"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"

A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.

warrants financial

"granted an aggregate of 29,380 warrants to certain employees"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

ordinary share financial

"Each Warrant confers the right to subscribe for one ordinary share"

An ordinary share is a unit of ownership in a company that gives the holder a stake in its profits and usually the right to vote on key decisions. Think of it like a slice of a pizza where each slice entitles you to a portion of what’s left after bills are paid; value can rise or fall with the business and may pay dividends, so it matters to investors for income, growth and control.

Articles of Association regulatory

"under the terms of Appendix 1a to the Company’s Articles of Association"

A company's articles of association are its written rulebook that sets how the business is run, how decisions are made, and what rights owners and directors have—covering voting, meetings, appointment and removal of directors, share classes and dividend policies. For investors, these rules matter because they determine how easily control can change, what protections minority owners have, and how corporate actions (like issuing new shares or changing leadership) are approved, much like a home’s bylaws shaping what residents can and cannot do.

FAQ

What did Ascendis Pharma (ASND) announce in the September 2026 Form 6-K?

Ascendis Pharma reported that its board granted 29,380 employee warrants on September 8, 2026, each for one ordinary share at an exercise price of $270.09, and amended its Articles of Association to provide for these warrants.

What is the exercise price of the new Ascendis Pharma (ASND) warrants?

The new warrants have an exercise price of $270.09 per share, matching the closing price of Ascendis Pharma’s ordinary shares on the September 8, 2026 grant date.

How do the Ascendis Pharma (ASND) warrants vest for employees?

For the 29,380 warrants, 25% vest on the one‑year anniversary of the grant date. The remaining 75% vest at a rate of 1/36th per month starting one year after grant, subject to continued service, with earlier vesting possible upon certain exit events.

How many additional Ascendis Pharma (ASND) warrants remain available for future grants?

After this grant, warrants to subscribe for an additional 1,495,063 shares of Ascendis Pharma remain available for future grant under the company’s Articles of Association.

Does Ascendis Pharma (ASND) incorporate this Form 6-K into existing registration statements?

Yes. This Form 6-K is incorporated by reference into Ascendis Pharma’s registration statements on Form S-8 and Form F-3, becoming part of those registration statements from the filing date to the extent not later superseded.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/09/2026 - 04:04 PM Accepted by SEC EDGAR 09/09/2026 - 04:03 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September, 2026

Commission File Number: 001-36815

Ascendis Pharma A/S

(Translation of registrant’s name into English)

Tuborg Boulevard 12

DK-2900 Hellerup

Denmark

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒   Form 40-F ☐

INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form S-8 (Registration Numbers 333-203040, 333-210810, 333-211512, 333-213412, 333-214843, 333-216883, 333-228576, 333-254101, 333-261550, 333-270088, 333-277519, 333-281916, 333-285322 and 333-293854) and Form F-3 (Registration Numbers 333-209336 and 333-282196) of Ascendis Pharma A/S (the “Company”) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Warrant Grants

On September 8, 2026, the Company’s board of directors granted an aggregate of 29,380 warrants to certain employees of the Company (the “Warrants”) under the terms of Appendix 1a to the Company’s Articles of Association. In connection with the grant of these Warrants, the Company amended its Articles of Association to provide for the grant of these Warrants. Each Warrant confers the right to subscribe for one ordinary share of the Company and has an exercise price equal to US $270.09 per share, the closing price of the Company’s ordinary shares as reported on the date of grant. Subject to earlier vesting upon the occurrence of certain exit events, 25% of the Warrants will vest on the one year anniversary of the date of grant and the remaining 75% will vest at a rate of 1/36th per month from one year after the date of grant, subject to continued service.

After giving effect to the grant of the Warrants described above, warrants to subscribe for an additional 1,495,063 shares of the Company remain available for future grant by the Company’s board of directors pursuant to the Company’s Articles of Association. The foregoing description of the material terms of the Warrants is qualified in its entirety by reference to the Company’s Articles of Association, which is included as Exhibit 1.1 hereto and incorporated by reference herein.

Exhibits

Exhibit No.		Description
1.1		Articles of Association.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Ascendis Pharma A/S
Date: September 9, 2026				By:		/s/ Michael Wolff Jensen
						Michael Wolff Jensen
						Executive Vice President, Chief Legal Officer

Filing Exhibits & Attachments

1 document

Other Documents

• EX-1.1 EX-1.1 504.6 KB